Sa'ar Yaniv

Stock Analyst at Roth Capital

(1.60)
# 3,066
Out of 4,789 analysts
3
Total ratings
33.33%
Success rate
4.06%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Sa'ar Yaniv

Galectin Therapeutics
Oct 19, 2017
Initiates: Buy
Price Target: $8
Current: $1.32
Upside: +506.06%